Open AccessCytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors inBRAFMutant Thyroid Carcinoma Cells
Author(s) -
Paolo Salerno,
Valentina De Falco,
Anna Tamburrino,
Tito Claudio Nappi,
Giancarlo Vecchio,
Rebecca E. Schweppe,
Gideon Bollag,
Massimo Santoro,
Giuliana Salvatore
Publication year - 2009
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2009-0373
Subject(s) - thyroid carcinoma , neuroblastoma ras viral oncogene homolog , thyroid cancer , cancer research , hras , mapk/erk pathway , endocrinology , kinase , medicine , v600e , cell culture , context (archaeology) , cell growth , biology , thyroid , cancer , kras , mutation , microbiology and biotechnology , biochemistry , genetics , gene , colorectal cancer , paleontology
The V600E mutation accounts for the vast majority of thyroid carcinoma-associated BRAF mutations.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom